Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q4 2022 Earnings Presentation
16 slides from Bonesupport Holding Ab's earnings presentation, Feb 16, 2023
Slide 1: Q4 (2022) Report
BONESUPPORT Q4 (2022) Report February 16th , 2023 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – Fourth quarter report 2022
BONESUPPORT – Fourth quarter report 2022 Q4 2022: • Net sales SEK 103,2 m, growth: +68% versus Q4 2021, (+49% in constant exchange rates, CER) • Operating result (before incentive provisions): SEK -10,1 m (SEK -17,0 m) • Reported EBIT: SEK -19,3 m (SEK -21,8 m) Full year 2022: • Net sales SEK 328,8
Slide 4: Q4 2022: Ten consecutive all-time-highs and acceleration in growth rates
Q4 2022: Ten consecutive all-time-highs and acceleration in growth rates LTM Quarterly Sales per Segment • Full year 2022 sales: 350 329 350 m 329 SEK 325 325 300 287 300 Sales growth of 54 % 275 257 275 250 234 250 • First quarter of CERAMENT G 213 Net Sales, SEK m Net Sales, SEK m 225 225 sales in
Slide 5: North America: Expansion of customer base and launch of CERAMENT G
North America: Expansion of customer base and launch of CERAMENT G Q4 2022 • Sales of SEK 73,4 m, growth of 111% over Q4 2021, growth of 80% in constant exchange rate, CER • Sales in Q4 2022 represented a reported sequential growth of 30% over Q3 2022 • Sales of CERAMENT G: 14,5 mSEK Highlight: CERA
Slide 6: CERAMENT G launched in the US
CERAMENT G launched in the US Market penetration dynamics: Contracts/ Hospital system Surgeon Q4 2022 sales listings approvals promotion CERAMENT G in US: SEK 14,5 m Group Purchasing Hospital groups: i.e. Training Trial Evaluation Regular use Organization: i.e Cleveland Clinic Premier, HealthTrust Q
Slide 7: EUROW: Weak recovery in general surgical procedures
EUROW Weak recovery in general surgical procedures Q4 2022 • Sales of SEK 29,8 m, growth of 12% vs Q4 2021, +9% in constant exchange rates, CER • The general surgery capacity recovery seen during Q3, in several regions, was not continued in Q4 • Staffing challenges accentuated by nursing strikes (UK
Slide 8: Financial Report
BONESUPPORT Q4 (2022) Report Financial Report
Slide 9: Q4 2022 net sales SEK 103.2 m
Q4 2022 net sales SEK 103.2 m SEK m • NA: 111 percent reported growth. 80 percent growth in CER • EUROW: 12 percent reported growth. 9 percent growth CER • High impact from currency movements 9
Slide 10: Net sales and gross margin by region
North America +111% EUROW +12% (+80% CER) (+9% CER) Net sales Net sales Q4-22 Q4-22 North America 2022 2021 EUROW 2022 2021 SEK m Q4-22 Q3-22 Q2-22 Q1-22 Q4-21 SEK m Q4-22 Q3-22 Q2-22 Q1-22 Q4-21 Net Sales 73,4 56,3 46,0 41,2 34,8 Net Sales 29,8 28,3 28,6 25,2 26,6 Gross profit 69,4 53,1 42,9 38,6 3
Slide 11: Q4 expenses growth driven by market investments and currency impact
Q4 expenses growth driven by market investments and currency impact Key Figures 2022 2021 SEK m Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Selling expenses (less commissions and fees) 46,8 38,8 37,4 35,2 35,4 33,1 32,5 30,4 Sales Commissions and Fees 28,1 21,1 16,8 14,3 13,9 11,8 10,5 8,9 Research and Development expe
Slide 12: A SEK 6.9 m underlying profit improvement
A SEK 6.9 m underlying profit improvement Key Figures 2022 2021 SEK m Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Net Sales 103,2 84,6 74,6 66,3 61,4 54,9 51,8 44,8 Gross Margin (%) 91,5 90,8 89,0 90,5 89,3 89,0 89,5 88,6 Operating Loss -19,3 -13,9 -14,9 -16,5 -21,8 -13,3 -25,9 -19,7 Adj. Operating profit (i) -10,1 -4,
Slide 13: Currency effects between Q3 2022 and Q4 2022
To be noted: in this report there is a substantial movement between Q3 2022 and Q4 2022, following realized and unrealized currency effects from conversion of net assets, reported as Other operating income and other operating expense. Moving from a favorable SEK 2.4 million in Q3 2022 to a negative
Slide 14: Clear Corporate Strategy Driving Value Creation
BONESUPPORT Q4 (2022) Report Clear Corporate Strategy Driving Value Creation
Slide 15: BONESUPPORT – exciting journey ahead
BONESUPPORT – exciting journey ahead • CERAMENT G (Gentamicin) launched in the US T R E AT M E N T P R E F E R E N C E – Clinical superiority to standard of care 92% – Addresses an immediate and unmet clinical need – Breakthrough technology with incremental reimbursement (NTAP) 92% of US orthopedic
Slide 16: Q&A
BONESUPPORT Q4 (2022) Report Q&A